Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study-Reference-Cited by-同舟云学术

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

Published:2016-06 Issue:6 Volume:67 Page:912-924
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Provenzano Robert,Besarab Anatole,Wright Steven,Dua Sohan,Zeig Steven,Nguyen Peter,Poole Lona,Saikali Khalil G.,Saha Gopal,Hemmerich Stefan,Szczech Lynda,Yu K.H. Peony,Neff Thomas B.

Publisher

Elsevier BV

Subject

Nephrology

Reference37 articles.

1. Red blood cell transfusion use in patients with chronic kidney disease;Gill;Nephrol Dial Transplant,2013

2. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin;Besarab;N Engl J Med,1998

3. Correction of anemia with epoetin alfa in chronic kidney disease;Singh;N Engl J Med,2006

4. Normalization of hemoglobin level in patients with chronic kidney disease and anemia;Drueke;N Engl J Med,2006

5. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease;Pfeffer;N Engl J Med,2009

Cited by 223 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease;Biomedicines;2024-08-18

2. Efficacy and Safety of Roxadustat Compared to Erythropoiesis-Stimulating Agents in the Treatment of Renal Anaemia in Haemodialysis Patients: A Meta-Analysis;International Journal of Pharmacology;2024-08-01

3. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis;Frontiers in Pharmacology;2024-07-10

4. Erythropoiesis‐stimulating agent hyporesponsiveness was associated with worse survival of hemodialysis patients independent of the serum ferritin level;Therapeutic Apheresis and Dialysis;2024-07-04

5. A spotlight on using HIF-PH inhibitors in renal anemia;Expert Opinion on Pharmacotherapy;2024-07-02